Solid Biosciences Inc. Increase Decrease In Operating Lease Liability
Solid Biosciences Inc. (SLDB) reported Increase Decrease In Operating Lease Liability of -$1.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06
- Solid Biosciences Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$510.00K.
- Solid Biosciences Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$496.00K.
- Solid Biosciences Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$495.00K.
- Solid Biosciences Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$443.00K.
- Solid Biosciences Inc. increase decrease in operating lease liability for fiscal 2025 was -$1.79M.
- Solid Biosciences Inc. increase decrease in operating lease liability for fiscal 2024 was -$1.68M.
- Solid Biosciences Inc. increase decrease in operating lease liability for fiscal 2023 was -$1.74M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$510.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.01M 10-Q · filed 2026-08-06 | -$1.50M derived: sum of 3 quarters · filed 2026-08-06 | -$1.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$496.00K 10-Q · filed 2026-05-12 | -$991.00K derived: sum of 2 quarters · filed 2026-05-12 | -$1.43M derived: sum of 3 quarters · filed 2026-05-12 | -$1.87M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$495.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$938.00K derived: sum of 2 quarters · filed 2026-03-19 | -$1.37M derived: sum of 3 quarters · filed 2026-08-06 | -$1.79M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$443.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$875.00K derived: sum of 2 quarters · filed 2026-08-06 | -$1.29M 10-Q · filed 2025-11-03 | -$1.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$432.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$848.00K 10-Q · filed 2026-08-06 | -$1.26M derived: sum of 3 quarters · filed 2026-08-06 | -$1.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$416.00K 10-Q · filed 2026-05-12 | -$830.00K derived: sum of 2 quarters · filed 2026-05-12 | -$1.23M derived: sum of 3 quarters · filed 2026-05-12 | -$1.62M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$414.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$812.00K derived: sum of 2 quarters · filed 2026-03-19 | -$1.20M derived: sum of 3 quarters · filed 2026-03-19 | -$1.68M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$398.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$789.00K derived: sum of 2 quarters · filed 2025-11-03 | -$1.26M 10-Q · filed 2025-11-03 | -$1.74M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | -$391.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$864.00K 10-Q · filed 2025-08-12 | -$1.34M derived: sum of 3 quarters · filed 2025-08-12 | -$1.78M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$473.00K 10-Q · filed 2025-05-15 | -$947.00K derived: sum of 2 quarters · filed 2025-05-15 | -$1.39M derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$474.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$918.00K derived: sum of 2 quarters · filed 2025-03-06 | -$1.74M 10-K · filed 2025-03-06 | |
| 2023-09-30 | -$444.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$1.26M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | -$817.00K 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |